Adverts

Open Access Articles- Top Results for Ritanserin

Ritanserin

</th></tr>
Ritanserin
File:Ritanserin2DCSD.svg
Systematic (IUPAC) name
6-[2-[4-[bis(4-fluorophenyl)methylidene]piperidin-1-yl]ethyl]-7-methyl-[1,3]thiazolo[2,3-b]pyrimidin-5-one
Clinical data
Identifiers
87051-43-2 7pxY
None
PubChem CID 5074
IUPHAR ligand 97
ChemSpider 4896 7pxN
UNII 145TFV465S 7pxY
ChEBI CHEBI:64195 7pxN
ChEMBL CHEMBL267777 7pxN
Chemical data
477.569 g/mol
 14pxN (what is this?)  (verify)

Ritanserin is a serotonin antagonist with possibilities for the treatment of many neurological disorders.

When used together with typical antipsychotics in the treatment of schizophrenia, it is able to decrease negative symptoms and adds some "atypicality" as parkinsonism is slightly decreased.

Ritanserin may also be effective in the prophylaxis of chronic migraine headaches. Its efficacy may be explained by its ability to antagonize 5-HT2 receptors.[1]

Pharmacology

Ritanserin acts as a 5-HT2A (Ki=0.45nM) and 5-HT2C receptor (Ki=0.71nM) antagonist, with higher affinity for the former site.[2]

See also

References

  1. ^ Nappi, G; Sandrini, G; Granella, F; Ruiz, L; Cerutti, G; Facchinetti, F; Blandini, F; Manzoni, GC (June 1990). "A new 5-HT2 antagonist (ritanserin) in the treatment of chronic headache with depression. A double-blind study vs amitriptyline.". Headache 30 (7): 439–44. PMID 2119355. doi:10.1111/j.1526-4610.1990.hed3007439.x. 
  2. ^ Akhondzadeh S, Malek-Hosseini M, Ghoreishi A, Raznahan M, Rezazadeh SA (September 2008). "Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: A double-blind randomized placebo-controlled study". Progress in neuro-psychopharmacology & biological psychiatry 32 (8): 1879–83. PMID 18801405. doi:10.1016/j.pnpbp.2008.08.020. 


Lua error in package.lua at line 80: module 'Module:Buffer' not found.